Salix to file antibiotic Xifaxan for IBS after Phase III success
This article was originally published in Scrip
Executive Summary
Salix Pharmaceuticals' broad spectrum antibiotic Xifaxan (rifaximin) met its primary endpoint in two Phase III trials, providing symptomatic relief from non-constipation irritable bowel syndrome (IBS). The company's share price soared by 51% to close at $20.22 on September 14th on Nasdaq following the news.